Skip to main content

Clinical Trials Using Dasatinib

Review the clinical trials studying dasatinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-20 of 20

Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Status: Active
Location: 194 locations
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment with Blinatumomab for Children, Adolescents, and Young Adults with Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Active
Location: 66 locations
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Status: Active
Location: 7 locations
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
Status: Active
Location: 4 locations
ASCIMINIB, Dasatinib, Prednisone, and Blinatumomab in Treating Patients with BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, or Chronic Myeloid Leukemia
Status: Active
Location: 4 locations
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Status: Active
Location: 3 locations
Adding Dasatinib or Venetoclax to Standard Chemotherapy for the Treatment in Children with T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoma or Mixed Phenotype Acute Leukemia, the SJALL23T Trial
Status: Active
Location: 3 locations
Inotuzumab Ozogamicin and Blinatumomab with Standard Chemotherapy in Treating Newly Diagnosed Patients with B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Status: Active
Location: 2 locations
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Status: Active
Location: 3 locations
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Dasatinib and Quercetin with CAR-T Therapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Brexucabtagene Autoleucel plus Dasatinib for the Treatment of Relapsed or Refractory B Acute Lymphoblastic Leukemia
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Palbociclib, Bortezomib, Dexamethasone, and Doxorubicin for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia, RELPALL2 Study
Status: Active
Location: Lucile Packard Children's Hospital Stanford University, Palo Alto, California
Medication Combinations of Dasatinib, Quercetin, Fisetin and Temozolomide for the Treatment of Previously Treated Glioma with Residual Disease
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Asciminib Roll-over Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Dasatinib and Venetoclax in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Chemotherapy-free Induction Regimen and Inotuzumab Ozogamicin for the Treatment of Ph+ Acute Lymphoblastic Leukemia
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Autophagy Therapeutics (Hydroxychloroquine, Nelfinavir, Metformin, Dasatinib, and Sirolimus) for the Treatment of Advanced Solid Tumors or Relapsed Prostate Cancer
Status: Temporarily Closed to Accrual
Location: Medical University of South Carolina, Charleston, South Carolina